Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
Abstract ERBB2 (HER2) represents a newly recognized actionable oncogenic driver in non-small cell lung cancer (NSCLC), with approved targeted therapy available. Understanding the landscape of ERBB2 alterations and co-occurring mutations is essential for guiding treatment decisions. We conducted an a...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2024-10-01
|
| Seri Bilgileri: | npj Precision Oncology |
| Online Erişim: | https://doi.org/10.1038/s41698-024-00720-9 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|